K. Kajinami

发表

Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor.

K. Kajinami, N. Takekoshi, Yasushi Saito, 2006, Cardiovascular drug reviews.

Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. Hokuriku NK-104 Study Group.

H. Mabuchi, J. Koizumi, K. Kajinami, 2000, The American journal of cardiology.

Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia.

H. Mabuchi, A. Nohara, Akihiro Inazu, 2002, Atherosclerosis.

Noninvasive prediction of coronary atherosclerosis by quantification of coronary artery calcification using electron beam computed tomography: comparison with electrocardiographic and thallium exercise stress test results.

H. Mabuchi, K. Kajinami, N. Takekoshi, 1995, Journal of the American College of Cardiology.

ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin Published, JLR Papers in Press, January 1, 2004. DOI 10.1194/jlr.M300278-JLR200

J. Ordovás, E. Schaefer, K. Kajinami, 2004, Journal of Lipid Research.

18F-FDG PET/CT for Detecting Sarcoma of the Aorta in a Patient with Takayasu Arteritis

H. Tonami, K. Kajinami, N. Watanabe, 2016, Nuclear Medicine and Molecular Imaging.

Increased levels of the oxidative stress marker, nitrotyrosine in patients with provocation test-induced coronary vasospasm.

Kenichi Yoshida, K. Kajinami, Makoto Watanabe, 2014, Journal of cardiology.

Circulating Matrix Metalloproteinases and Their Inhibitors in Premature Coronary Atherosclerosis

H. Mabuchi, Akihiro Inazu, J. Koizumi, 2001, Clinical chemistry and laboratory medicine.

Possibly Late-Onset Arrhythmogenic Right Ventricular Cardiomyopathy: Unique Triglyceride Deposition by Analysis of Lipid Contents

K. Kajinami, N. Kurose, S. Yamada, 2019, Clinical medicine insights. Case reports.

Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner.

J. Ordovás, E. Schaefer, K. Kajinami, 2004, The American journal of cardiology.

Prediction of all-cause death using 11C-hydroxyephedrine positron emission tomography in Japanese patients with left ventricular dysfunction

S. Nekolla, I. Matsunari, K. Kajinami, 2016, Annals of Nuclear Medicine.

Effects of CS-514 on serum lipoprotein lipid and apolipoprotein levels in patients with familial hypercholesterolemia.

H. Mabuchi, T. Wakasugi, K. Kajinami, 1987, Metabolism: clinical and experimental.

Removal of apolipoprotein E-enriched high density lipoprotein by LDL-apheresis in familial hypercholesterolaemia: a possible activation of the reverse cholesterol transport system.

H. Mabuchi, Akihiro Inazu, J. Koizumi, 1988, Atherosclerosis.

Myocardial glucose metabolism assessed by positron emission tomography and the histopathologic findings of microvessels in syndrome X.

K. Kajinami, N. Takekoshi, S. Kanemitsu, 2004 .

Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus

K. Kajinami, Y. Kawai, A. Motoyama, 2011, Drug design, development and therapy.

Serum deoxyribonuclease I activity can be a useful diagnostic marker for the early diagnosis of unstable angina pectoris or non-ST-segment elevation myocardial infarction.

T. Yasuda, K. Kajinami, M. Ueki, 2012, Journal of cardiology.

ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin

J. Ordovás, E. Schaefer, K. Kajinami, 2004 .

Additive effects of another kind of HMG-CoA reductase inhibitor with different pharmacokinetics in the treatment of heterozygous familial hypercholesterolemia.

H. Mabuchi, Akihiro Inazu, J. Koizumi, 2000, Atherosclerosis.

Opposite effects on serum cholesteryl ester transfer protein levels between long-term treatments with pravastatin and probucol in patients with primary hypercholesterolemia and xanthoma.

H. Mabuchi, Akihiro Inazu, J. Koizumi, 1999, Atherosclerosis.

Coronary calcification and coronary atherosclerosis: site by site comparative morphologic study of electron beam computed tomography and coronary angiography.

H. Mabuchi, K. Kajinami, N. Takekoshi, 1997, Journal of the American College of Cardiology.

Monitoring the roles of prothrombin activation fragment 1 and 2 (F1 + 2) in patients with atrial fibrillation receiving rivaroxaban and apixaban

N. Fujioka, K. Kajinami, Y. Kawai, 2020, Journal of Thrombosis and Thrombolysis.

Circulating Glutamate and Taurine Levels Are Associated with the Generation of Reactive Oxygen Species in Paroxysmal Atrial Fibrillation

N. Fujioka, K. Kajinami, Y. Kawai, 2016, Disease markers.

CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia.

J. Ordovás, E. Schaefer, K. Kajinami, 2004, The American journal of cardiology.

Serum deoxyribonuclease I activity can be used as a novel marker of transient myocardial ischaemia: results in vasospastic angina pectoris induced by provocation test.

T. Yasuda, I. Miyamori, K. Kajinami, 2007, European heart journal.

Diurnal glycemic fluctuation is associated with severity of coronary artery disease in prediabetic patients: Possible role of nitrotyrosine and glyceraldehyde-derived advanced glycation end products.

M. Takeuchi, K. Kajinami, Makoto Watanabe, 2017, Journal of cardiology.

Probucol: can we step forward in atherosclerosis prevention with an old drug?

K. Kajinami, H. Akao, Hironobu Akao, 2012, Atherosclerosis.

Levels of serum deoxyribonuclease I activity on admission in patients with acute myocardial infarction can be useful in predicting left ventricular enlargement due to remodeling.

T. Yasuda, M. Kurabayashi, S. Oshima, 2009, Journal of cardiology.

Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia

H. Mabuchi, J. Koizumi, K. Kajinami, 1998 .

Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group.

H. Mabuchi, J. Koizumi, K. Kajinami, 1998, The American journal of cardiology.

Serum lipoprotein lipid concentration and composition in homozygous and heterozygous patients with cholesteryl ester transfer protein deficiency.

A. Tall, H. Mabuchi, P. Moulin, 1991, Atherosclerosis.

Hokuriku-plus familial hypercholesterolaemia registry study: rationale and study design

K. Hayashi, M. Yamaguchi, H. Murai, 2020, BMJ Open.

Clinical efficacy and safety of cerivastatin in the treatment of heterozygous familial hypercholesterolemia.

H. Mabuchi, J. Koizumi, K. Kajinami, 1998, The American journal of cardiology.

Increased plasma glutamate in non-smokers with vasospastic angina pectoris is associated with plasma cystine and antioxidant capacity

K. Kajinami, Kazuyuki Saito, Y. Kawai, 2022, Scandinavian cardiovascular journal : SCJ.

Glyceraldehyde-derived advanced glycation end-products are associated with left ventricular ejection fraction and brain natriuretic peptide in patients with diabetic adverse cardiac remodeling

M. Takeuchi, K. Kajinami, Kazuyuki Saito, 2022, Scandinavian cardiovascular journal : SCJ.

New Variant of Low Density Lipoprotein Receptor Gene: FH×Tonami

H. Mabuchi, J. Koizumi, T. Wakasugi, 1988, Arteriosclerosis.

Novel gene mutations at the low density lipoprotein receptor locus: FH‐Kanazawa and FH‐Okayama

H. Mabuchi, Akihiro Inazu, J. Koizumi, 1990, Journal of internal medicine.

Abetalipoproteinemia caused by maternal isodisomy of chromosome 4q containing an intron 9 splice acceptor mutation in the microsomal triglyceride transfer protein gene.

H. Mabuchi, Akihiro Inazu, J. Koizumi, 1999, Arteriosclerosis, thrombosis, and vascular biology.

Reduction of lipoprotein(a) by LDL-apheresis using a dextran sulfate cellulose column in patients with familial hypercholesterolemia.

Akihiro Inazu, J. Koizumi, K. Kajinami, 1993, Atherosclerosis.

Hyperhomocysteinemia, diabetes mellitus, and carotid atherosclerosis independently increase atherosclerotic vascular disease outcome in Japanese patients with end-stage renal disease.

H. Mabuchi, Akihiro Inazu, J. Koizumi, 2001, Clinical nephrology.

Neuronal Imaging and Reverse Remodeling

I. Matsunari, K. Kajinami, W. Fujita, 2017 .

Plasma homocysteine level and development of coronary artery disease.

H. Mabuchi, Akihiro Inazu, J. Koizumi, 1999, Coronary artery disease.

Iodine-123 Metaiodobenzylguanidine Imaging and Carbon-11 Hydroxyephedrine Positron Emission Tomography Compared in Patients With Left Ventricular Dysfunction

S. Nekolla, K. Nakajima, J. Taki, 2010, Circulation. Cardiovascular imaging.

Towards Effective Cost-Effectiveness Analysis in Atherosclerotic Cardiovascular Disease Prevention.

K. Kajinami, 2018, Circulation journal : official journal of the Japanese Circulation Society.

Lipoprotein(a): Revisiting a Next Therapeutic Target.

K. Kajinami, 2016, Circulation journal : official journal of the Japanese Circulation Society.

Response to pre-dilatation with POBA can predict target lesion revascularization after DCB angioplasty for de novo small coronary artery lesions

K. Kajinami, T. Tsuchiya, Y. Kawai, 2022, The Journal of international medical research.

Serum apolipoproteins in heterozygous familial hypercholesterolemia.

H. Mabuchi, J. Koizumi, K. Kajinami, 1992, Clinica chimica acta; international journal of clinical chemistry.

A young type III hyperlipoproteinemic patient associated with apolipoprotein E deficiency.

H. Mabuchi, J. Koizumi, T. Wakasugi, 1989, Metabolism: clinical and experimental.

Enhanced Cholesteryl Ester Transfer Protein Activities and Abnormalities of High Density Lipoproteins in Familial Hypercholesterolemia

H. Mabuchi, Akihiro Inazu, J. Koizumi, 1992, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

Imbalance of sex hormone levels in men with coronary artery disease

K. Takeda, K. Kajinami, N. Takekoshi, 2004, Coronary artery disease.

Guidelines on the Clinical Evaluation of Medicinal Products for Treatment of Dyslipidemia

S. Yamashita, T. Okamura, H. Arai, 2020, Journal of atherosclerosis and thrombosis.

A family of familial hypercholesterolemia with cerebral infarction and without coronary heart disease An unusual case with corneal opacity, polyneuropathy and carpal tunnel syndrome in the family: Therapy with probucol and tocopherol nicotinate

H. Mabuchi, K. Kajinami, M. Kibata, 1991, Journal of the Neurological Sciences.

The circulating furin-cleaved/mature PCSK9 ratio has a potential prognostic significance in statin-naïve patients with acute ST elevation myocardial infarction

K. Kajinami, Y. Kawai, M. Kitayama, 2022, Atherosclerosis plus.

Propranolol for probucol-induced QT prolongation with polymorphic ventricular tachycardia

H. Mabuchi, K. Kajinami, N. Takekoshi, 1993, The Lancet.

Low-density lipoprotein receptor genotype-dependent response to cholesterol lowering by combined pravastatin and cholestyramine in familial hypercholesterolemia.

H. Mabuchi, Akihiro Inazu, J. Koizumi, 1998, The American journal of cardiology.

Circulating malondialdehyde-modified low-density lipoprotein (MDA-LDL) as a novel predictor of clinical outcome after endovascular therapy in patients with peripheral artery disease (PAD).

K. Kajinami, Makoto Watanabe, T. Tsuchiya, 2017, Atherosclerosis.

Quantitation of cardiac sympathetic innervation in rabbits using 11C-hydroxyephedrine PET: relation to 123I-MIBG uptake

S. Nekolla, K. Nakajima, J. Taki, 2006, European Journal of Nuclear Medicine and Molecular Imaging.

Evolocumab vs. Ezetimibe in Statin-Intolerant Hyperlipidemic Japanese Patients: Phase 3 GAUSS-4 Trial

S. Koba, K. Kajinami, M. Cyrille, 2019, Journal of atherosclerosis and thrombosis.

Therapeutic effects of LDL apheresis in the prevention of atherosclerosis.

H. Mabuchi, K. Kajinami, Hiroshi Mabuchi, 1999, Current opinion in lipidology.

Effects of CS-514 (eptastatin), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on serum lipid and apolipoprotein levels in heterozygous familial hypercholesterolemic patients treated by low density lipoprotein (LDL)-apheresis.

H. Mabuchi, J. Koizumi, K. Kajinami, 1988, Atherosclerosis.

Absence of familial defective apolipoprotein B-100 in Japanese patients with familial hypercholesterolaemia

H. Mabuchi, A. Nohara, Akihiro Inazu, 1995, The Lancet.

Monday, 27 August 2012

V. V. Ivanenko, E. A. Medvedeva, Michail I. Papafaklis, 2012 .

Mutations in the Low Density Lipoprotein Receptor Gene in Japanese Patients with Familial Hypercholesterolemia

H. Mabuchi, J. Koizumi, K. Kajinami, 1990, Annals of the New York Academy of Sciences.

A Case of Myopericarditis After the Second Dose of mRNA COVID-19 Vaccine in a Patient With a History of Myopericarditis

K. Kajinami, Kosuke Fujibayashi, 2022, Clinical medicine insights. Case reports.

Coronary ectasia in familial hypercholesterolemia: histopathologic study regarding matrix metalloproteinases.

H. Mabuchi, J. Koizumi, Y. Oda, 1999, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

Statin response and pharmacokinetics variants

H. Masuya, E. Schaefer, K. Takeda, 2005, Expert opinion on pharmacotherapy.

Chk1‐mediated phosphorylation of receptor‐associated late transducer at serine 250 increases its stability by stimulating its interaction with 14‐3‐3

Y. Ishigaki, K. Takeda, K. Kajinami, 2013, Genes to cells : devoted to molecular & cellular mechanisms.

Statin Intolerance Clinical Guide 2018

S. Yamashita, T. Nakayama, H. Saito, 2020, Journal of atherosclerosis and thrombosis.

Angioedema likely related to angiotensin converting enzyme inhibitors.

K. Kajinami, M. Matsumura, T. Takada, 1993, Internal medicine.

Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin.

J. Ordovás, E. Schaefer, K. Kajinami, 2004, Atherosclerosis.

Role of a novel conduction pattern around the coronary sinus in cavotricuspid isthmus dependent right atrial flutter.

N. Fujioka, K. Kajinami, K. Kaseno, 2007, Journal of Cardiology.

A case of coronary rupture and pseudoaneurysm formation after fracture of implanted paclitaxel-eluting stents

K. Kajinami, T. Tsuchiya, M. Kitayama, 2016, Cardiovascular Intervention and Therapeutics.

Catalytically inactive lecithin: cholesterol acyltransferase (LCAT) caused by a Gly 30 to Ser mutation in a family with LCAT deficiency.

H. Mabuchi, Akihiro Inazu, J. Koizumi, 1997, Journal of lipid research.

Clinical characteristics of double heterozygotes with familial hypercholesterolemia and cholesteryl ester transfer protein deficiency.

H. Mabuchi, Akihiro Inazu, J. Koizumi, 1997, Atherosclerosis.

Synergy of aldosterone and high salt induces vascular smooth muscle hypertrophy through up-regulation of NOX1

C. Yabe-Nishimura, T. Yasuda, I. Miyamori, 2008, The Journal of Steroid Biochemistry and Molecular Biology.

Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency Published, JLR Papers in Press, December 1, 2003. DOI 10.1194/jlr.M300198-JLR200

E. Schaefer, H. Mabuchi, Akihiro Inazu, 2004, Journal of Lipid Research.

Effect of pretreatment vitamin D levels on in vivo effects of atorvastatin on bone metabolism in patients with heterozygous familial hypercholesterolemia.

K. Kajinami, N. Takekoshi, S. Kanemitsu, 2003, The American journal of cardiology.

ABCA1 gene variation and heart disease risk reduction in the elderly during pravastatin treatment.

A. D. de Craen, J. Jukema, E. Schaefer, 2014, Atherosclerosis.

Genetic variation at the SLCO1B1 gene locus and low density lipoprotein cholesterol lowering response to pravastatin in the elderly.

A. D. de Craen, R. Westendorp, J. Jukema, 2011, Atherosclerosis.

KIF6, LPA, TAS2R50, and VAMP8 genetic variation, low density lipoprotein cholesterol lowering response to pravastatin, and heart disease risk reduction in the elderly.

A. D. de Craen, J. Jukema, R. Westendorp, 2011, Atherosclerosis.

Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension.

Y. Kihara, Takeshi Yamamoto, Y. Takeishi, 2017, Circulation journal : official journal of the Japanese Circulation Society.

A Case Showing Increased Shock Lead Impedance Measures with Combination of a High Impedance Lead and Different Methods to Evaluate Lead Impedance

N. Fujioka, K. Kajinami, Kosuke Fujibayashi, 2022, Japanese Journal of Electrocardiology.

Asymptomatic congenital subclavian steal in a young male patient with right aortic arch.

K. Kajinami, K. Mori, Y. Itoh, 1990, Chest.

Clinical efficacy of fluvastatin in the long-term treatment of familial hypercholesterolemia.

Akihiro Inazu, J. Koizumi, K. Kajinami, 1995, The American journal of cardiology.

A possible role for HLA-DRB1*04:06 in statin-related myopathy in Japanese patients.

K. Hirata, T. Akasaka, J. Oyama, 2016, Drug metabolism and pharmacokinetics.

Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients.

K. Maeda, H. Kusuhara, Y. Sugiyama, 2019, Drug metabolism and pharmacokinetics.

NK-104: a novel synthetic HMG-CoA reductase inhibitor

H. Mabuchi, K. Kajinami, Y. Saito, 2000, Expert opinion on investigational drugs.

Treatment Patterns, Statin Intolerance, and Subsequent Cardiovascular Events Among Japanese Patients With High Cardiovascular Risk Initiating Statin Therapy.

K. Fox, J. Meyers, K. Kajinami, 2017, Circulation journal : official journal of the Japanese Circulation Society.

Real-World Data to Identify Hypercholesterolemia Patients on Suboptimal Statin Therapy

S. Yamashita, H. Arai, K. Kajinami, 2019, Journal of atherosclerosis and thrombosis.

Molecular Genetics of Cholesterol Transport and Cholesterol Reverse Transport Disorders, and Coronary Heart Disease

H. Mabuchi, Akihiro Inazu, J. Koizumi, 1996 .

Molecular Genetics of Cholesterol Transport and Cholesterol Reverse Transport Disorders (Familial Hypercholesterolemia and CETP Deficiency) and Coronary Heart Disease

H. Mabuchi, Akihiro Inazu, J. Koizumi, 1994 .

Effects of serum B vitamins on elevated plasma homocysteine levels associated with the mutation of methylenetetrahydrofolate reductase gene in Japanese.

H. Iso, T. Okamura, H. Mabuchi, 2002, Atherosclerosis.

Nutri-pharmacogenomics of warfarin anticoagulation therapy: VKORC1 genotype-dependent influence of dietary vitamin K intake

K. Takeda, N. Fujioka, K. Kajinami, 2014, Journal of Thrombosis and Thrombolysis.

Pharmacogenomics of statin responsiveness.

E. Schaefer, K. Kajinami, E. Polisecki, 2005, The American journal of cardiology.

Gender-specific effects of estrogen receptor alpha gene haplotype on high-density lipoprotein cholesterol response to atorvastatin: interaction with apolipoprotein AI gene polymorphism.

J. Ordovás, E. Schaefer, S. Lamon-Fava, 2005, Atherosclerosis.

Ultrafast computed tomography in the diagnosis and evaluation of anomalous origin of the right coronary artery.

H. Mabuchi, K. Kajinami, H. Ino, 1995, Japanese heart journal.

[Genotype-phenotype correlations in familial hypercholesterolemia].

K. Kajinami, 1999, Nihon rinsho. Japanese journal of clinical medicine.

Myocardial sympathetic innervation, function, and oxidative metabolism in non-infarcted myocardium in patients with prior myocardial infarction

S. Nekolla, I. Matsunari, K. Kajinami, 2013, Annals of Nuclear Medicine.

A promoter polymorphism in cholesterol 7alpha-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin.

J. Ordovás, E. Schaefer, K. Kajinami, 2005, Atherosclerosis.

Effect of common methylenetetrahydrofolate reductase gene mutation on coronary artery disease in familial hypercholesterolemia.

H. Mabuchi, A. Nohara, Akihiro Inazu, 2000, The American journal of cardiology.

A 4-year trial of simvastatin in the treatment of patients with heterozygous familial hypercholesterolemia

H. Mabuchi, Akihiro Inazu, J. Koizumi, 1996 .

Quantification of coronary artery calcification using ultrafast computed tomography: Reproducibility of measurements

H. Mabuchi, K. Kajinami, N. Takekoshi, 1993, Coronary artery disease.

Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management.

E. Schaefer, K. Kajinami, N. Takekoshi, 2004, Atherosclerosis.

Common Mutation of 5, 10-Methylenetetrahydrofolate Reductase Accelerates Coronary Artery Disease in Familial Hypercholesterolemia

H. Mabuchi, A. Nohara, Akihiro Inazu, 2000 .

Statin pharmacogenomics: what have we learned, and what remains unanswered?

E. Schaefer, K. Kajinami, E. Polisecki, 2005, Current opinion in lipidology.

Long-term probucol treatment results in regression of xanthomas, but in progression of coronary atherosclerosis in a heterozygous patient with familial hypercholesterolemia.

H. Mabuchi, J. Koizumi, K. Kajinami, 1996, Atherosclerosis.

[A case of tsutsugamushi disease in the urban area of Komatsu City].

K. Kajinami, H. Fujita, K. Ueda, 1991, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases.

Cholesterol absorption inhibitors in development as potential therapeutics

K. Kajinami, N. Takekoshi, 2002, Expert opinion on investigational drugs.

Microvascular ischemia in patients with myotonic dystrophy.

K. Kajinami, H. Ino, K. Yagi, 2000, Japanese circulation journal.

Serum deoxyribonuclease I activity can be used as a novel marker of transient myocardial ischaemia: results in vasospastic angina pectoris induced by provocation test.

K. Kajinami, H. Takeshita, Y. Kominato, 2007, European heart journal.

Real-World Data to Identify Hypercholesterolemia Patients on Suboptimal Statin Therapy

S. Yamashita, H. Arai, K. Kajinami, 2019, Journal of atherosclerosis and thrombosis.